PTCT
PTC THERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$61.53
+3.87%Year over year
Reported trailing growth
- Revenue
- -42.8%
- EBITDA
- -79.4%
- EBIT
- -83.8%
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +26.8%
- EBITDA
- +173.3%
- EPS
- +425.8%
Three-year CAGR
- Revenue
- +35.3%
- EBITDA
- +836.9%
- EBIT
- +383.1%
- Net income
- +287.9%
- EPS
- +281.4%
- Free cash flow
- +326.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026